/EINPresswire.com/ -- CLEVELAND, OH--(Marketwired - November 10, 2015) - DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trial industry, today provided an update on its lawsuit against Medidata Solutions, Inc. for unauthorized use of DATATRAK's intellectual property in the Medidata Rave™ and Medidata CTMS™ platforms.

On November 6, 2015, the U.S. District for the Northern District of Ohio issued a ruling granting Medidata's motion to dismiss DATATRAK's action for infringement of U.S. Patent No. 7,464,087 ("the '087 Patent"), which covers systems and methods for unifying data. The ruling found claims of the Patent invalid on the grounds that they are not directed to patentable subject matter, notwithstanding the fact such claims successfully survived a reexamination challenge through a decision of the Board of Patent Appeals and Interferences in 2014. The Court's ruling is based upon the Supreme Court's 2014 decision in Alice Corp. Pty. Ltd. v CLS Bank International, which was issued over three years after the case was filed in 2011. As a result, the Court entered judgment in favor of Medidata in the case without reaching the merits of DATATRAK's infringement contentions.

"We are disappointed in, and strongly disagree with, the Court's analysis in finding the '087 Patent claims invalid and plan to appeal the decision," said Chairman and CEO, Laurence P. Birch.

Mr. Birch continued, "It is important to note that only certain claims of the '087 Patent were at issue in this case and that DATATRAK's patent portfolio includes several other key patents and pending applications. DATATRAK is committed to protecting its intellectual property and, with that goal in mind, we will be evaluating the patents in our portfolio with the benefit of this decision and its reasoning."

About DATATRAK

DATATRAK International is a worldwide technology and services Company delivering Unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Chicago, IL; Cary Research Triangle Park (RTP), North Carolina; Bryan, Texas; and Cleveland, Ohio. For more information, visit http://www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:

Dorothy Radke
Director Marketing
DATATRAK International, Inc.
+1-440-443-0082

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.